How Will AI Enhance Clinical Trial Recruitment?

Pharma leader Eli Lilly has invested in healthcare AI company Abridge as the companies work to apply ambient clinical documentation technology to clinical trial recruitment, according to announcements from Abridge and reporting by STAT and Endpoints.

The investment extends Abridge's role beyond medical documentation and into research operations. The Pittsburgh-based company is known for software that records and structures physician-patient conversations into clinical notes and electronic health record workflows. It now plans to use the same technology to help identify patients who may qualify for clinical trials.

Abridge announced the collaboration during a broader product expansion that also included new partnerships with NVIDIA and other healthcare technology providers.

The move reflects growing interest among pharmaceutical companies in using AI to address one of the industry's most persistent challenges: finding eligible patients for clinical studies. According to Endpoints, Lilly's investment is tied to efforts to improve trial recruitment by identifying potential participants from clinical conversations and medical records.

From Documentation to Research Workflows

Abridge was founded in 2018 and initially focused on reducing clinician documentation workloads through ambient AI technology. The company raised a $150 million Series C round in 2024 and has since expanded its presence across U.S. health systems.

Its technology listens to physician-patient conversations, generates structured documentation, and integrates information into clinical workflows. That foundation helped drive deployments across major healthcare organizations and partnerships with electronic health record providers.

The company's evolution mirrors broader activity across the healthcare AI sector. Ambient documentation vendors have increasingly expanded into adjacent operational functions as health systems look for additional uses beyond note generation.

Health systems have also continued adopting AI tools directly inside electronic health record environments to reduce administrative work and improve clinical efficiency.

Trial Recruitment Remains a Major Challenge

Clinical trial recruitment remains one of the largest operational barriers in drug development. Sponsors frequently struggle to identify eligible participants and enroll them quickly enough to keep studies on schedule.

Lilly's investment suggests the company sees ambient clinical data as a potential source of recruitment intelligence. Rather than relying solely on traditional outreach methods, AI systems could help surface patients whose clinical histories align with study eligibility requirements during routine care interactions.

The announcement comes as pharmaceutical companies and healthcare organizations continue increasing investments in AI infrastructure and workflow automation. Roche, for example, recently expanded its AI computing capacity with a large-scale deployment of NVIDIA Blackwell graphics processing units to support research and operational workloads.

Abridge has also attracted significant investor interest. In addition to its 2024 financing, the company announced a $300 million funding round in 2025 that valued the business at approximately $5.3 billion.

Whether AI-assisted identification leads to faster enrollment remains to be seen. Patient recruitment involves regulatory review, site capacity, screening procedures, and informed consent processes that extend beyond initial patient matching.

For Lilly, however, the investment signals that ambient AI is becoming part of the clinical trial technology stack. As healthcare organizations continue deploying AI systems across documentation, operations, and research, clinical trial recruitment is emerging as another area where companies are testing whether data generated during routine care can support drug development.